Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

Inclusion Criteria: * informed consent signed * age \> 30 but \< 85 years * significant angina pectoris (CCS 2-3) despite of optimal medication * significant stenosis (\> 60%) in coronary angiography (\< 6 months) * contraindication to CABG or PCI due to diffuse or distal stenosis, chronic total occlusion, vessels with difficult anatomy, stenosis with severe calcifications and stenosis in small vessels (\<2.5 mm)) * angina pectoris or equivalent symptoms in the 6-minute walking exercise test * left ventricle wall \> 8 mm detected by transthoracic echocardiography or magnetic resonance imaging (treatment area) Exclusion Criteria: * women in fertile age * diabetes mellitus with severe complications such as diabetic retinopathy or nephropathy * clinically significant anemia (hemoglobin count \< 120 mg/l in male, \< 110 mg/l in female; hematocrit \< 0.36), leukopenia (b-leukocyte count \< 3.0x109/l), leukocytosis (b-leukocyte count \> 12.0x109/l) or thrombocytopenia (b-thrombocyte count \< 100x109/l) * renal insufficiency (P-creatinine \> 160 mg/l) * liver insufficiency (P-alanine aminotransferase or P-alkaline phosphatase over 2 x normal) * haematuria of unknown origin * severe hypertension (systolic blood pressure \> 200 mmHg or diastolic blood pressure \> 110 mmHg) or significant hypotension (systolic blood pressure \< 90 mmHg) * significant obesity (Body Mass Index \> 35) * acute infection * immunosuppressive medication * significant impairment of left ventricular function…